These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19954276)

  • 21. Current role of vigabatrin in infantile spasms.
    Parisi P; Bombardieri R; Curatolo P
    Eur J Paediatr Neurol; 2007 Nov; 11(6):331-6. PubMed ID: 17625936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of West syndrome].
    Cvitanović-Sojat L; Gjergja R; Sabol Z; Hajnzić TF; Sojat T
    Acta Med Croatica; 2005; 59(1):19-29. PubMed ID: 15813352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic trial of vigabatrin in refractory infantile spasms.
    Chiron C; Dulac O; Beaumont D; Palacios L; Pajot N; Mumford J
    J Child Neurol; 1991; Suppl 2():S52-9. PubMed ID: 1940125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of infantile spasms: new opportunities and emerging challenges.
    Mikati MA; Cornett KM
    Epilepsy Behav; 2010 Apr; 17(4):571-3. PubMed ID: 20097137
    [No Abstract]   [Full Text] [Related]  

  • 25. New drugs: pitavastatin calcium, vigabatrin, and romidepsin.
    Hussar DA; Christian ME
    J Am Pharm Assoc (2003); 2010; 50(4):548-51. PubMed ID: 20621877
    [No Abstract]   [Full Text] [Related]  

  • 26. Infantile spasms and vigabatrin. Visual field defects may be permanent.
    Lhatoo SD; Sander JW
    BMJ; 1999 Jan; 318(7175):57. PubMed ID: 10068225
    [No Abstract]   [Full Text] [Related]  

  • 27. Cerebral MRI abnormalities associated with vigabatrin therapy.
    Pearl PL; Vezina LG; Saneto RP; McCarter R; Molloy-Wells E; Heffron A; Trzcinski S; McClintock WM; Conry JA; Elling NJ; Goodkin HP; de Menezes MS; Ferri R; Gilles E; Kadom N; Gaillard WD
    Epilepsia; 2009 Feb; 50(2):184-94. PubMed ID: 18783433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binasal visual field defects are not specific to vigabatrin.
    Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
    Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-vision adverse events with vigabatrin therapy.
    Walker SD; Kälviäinen R
    Acta Neurol Scand Suppl; 2011; (192):72-82. PubMed ID: 22061182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update of the medical treatment of West syndrome.
    Verrotti A; Manco R; Coppola GG; Mingione S; Chiarelli F; Iannetti P
    Minerva Pediatr; 2007 Jun; 59(3):249-53. PubMed ID: 17519870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial.
    Darke K; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Lux AL; Newton RW; O'Callaghan FJ; Verity CM; Osborne JP;
    Arch Dis Child; 2010 May; 95(5):382-6. PubMed ID: 20457702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.
    Silverman RB
    J Med Chem; 2012 Jan; 55(2):567-75. PubMed ID: 22168767
    [No Abstract]   [Full Text] [Related]  

  • 33. [Therapeutic options provided by new antiepileptic drugs].
    Baulac M; Arzimanoglou A; Semah F; Cavalcanti D
    Rev Neurol (Paris); 1997 Feb; 153(1):21-33. PubMed ID: 9296153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unintended Consequences: The Story of PERF.
    Elterman RD; Shields WD
    Pediatr Neurol; 2015 Sep; 53(3):183-4. PubMed ID: 26149106
    [No Abstract]   [Full Text] [Related]  

  • 35. Vigabatrin pediatric dosing information for refractory complex partial seizures: results from a population dose-response analysis.
    Nielsen JC; Tolbert D; Patel M; Kowalski KG; Wesche DL
    Epilepsia; 2014 Dec; 55(12):e134-8. PubMed ID: 25311090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vigabatrin and epilepsy: further lessons in early childhood.
    Parisi P; Bombardieri R; Curatolo P
    Epilepsia; 2008 Jan; 49(1):177-8. PubMed ID: 18184225
    [No Abstract]   [Full Text] [Related]  

  • 37. Vigabatrin.
    Connelly JF
    Ann Pharmacother; 1993 Feb; 27(2):197-204. PubMed ID: 8439699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vigabatrin for childhood partial-onset epilepsies.
    Greiner HM; Lynch ER; Fordyce S; Agricola K; Tudor C; Franz DN; Krueger DA
    Pediatr Neurol; 2012 Feb; 46(2):83-8. PubMed ID: 22264701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment before seizures: new indications for antiepileptic therapy in children with tuberous sclerosis complex.
    Józwiak S; Domańska-Pakieła D; Kotulska K; Kaczorowska M
    Epilepsia; 2007 Aug; 48(8):1632; author reply 1632-4. PubMed ID: 17692054
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.